Tosin Abiodun Aderanti

Tosin Abiodun Aderanti

Auto-generated profile, based on publicly available information

Tosin Abiodun Aderanti

Department of Chemical and Environmental Sciences, Babcock University, Ilishan-Remo, Ogun State, Nigeria

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Journal of Medicine and Health Research
Verified
Journal Article
Closed access
HUHenry Okorie Ugorji
Henry Okorie Ugorji
AEAlex Nnanyelugo Egbuchiem
Alex Nnanyelugo Egbuchiem
GDGifty Dudzilah
Gifty Dudzilah
RORachael Boluwatife Oke
Rachael Boluwatife Oke
TATosin Abiodun Aderanti
Tosin Abiodun Aderanti
Children residing in agricultural settings are uniquely vulnerable to early-life exposure to agrochemicals, which may contribute to the development of pediatric cancers. This narrative review, incorporating systematic search and appraisal elements, synthesizes current evidence on the relationship between prenatal and early childhood agrochemical exposures and pediatric cancer risk, with a focus on predictive and spatial modeling approaches. A structured literature search was conducted across PubMed, Web of Science, Scopus, and Embase to identify epidemiologic, exposure modeling, and mechanistic studies published between 2000 and 2025. Epidemiologic evidence consistently implicates leukemia, particularly acute lymphoblastic leukemia, as the malignancy most strongly associated with early-life agrochemical exposure, while findings for central nervous system tumors and rarer pediatric cancers remain less consistent. Mechanistic studies support biological plausibility through pathways including genotoxicity, endocrine disruption, epigenetic reprogramming, and immune dysregulation during critical developmental windows. Predictive modeling approaches—ranging from traditional regression and Bayesian hierarchical models to machine learning and GIS-based methods—enhance exposure estimation, risk stratification, and identification of high-risk subgroups, though challenges persist related to exposure misclassification, chemical mixture assessment, and integration of mechanistic evidence. Overall, this review highlights key methodological gaps and research priorities, emphasizing the need for longitudinal, biomarker-validated studies and hybrid causal–predictive modeling frameworks. Advancing interdisciplinary, prevention-oriented research in this area is essential for informing evidence-based interventions, reducing pediatric cancer burden in agricultural populations, and promoting equitable environmental health outcomes.

10 April 2025 in Journal of Medicine and Health Research
Verified
Journal Article
Closed access
LALawrence John Ajutor
Lawrence John Ajutor
OGOluwaseun Shoyebo Gideon
Oluwaseun Shoyebo Gideon
OAOpeoluwa Alayande
Opeoluwa Alayande
TATosin Abiodun Aderanti
Tosin Abiodun Aderanti
EOEnobong Edoabasi Obong
Enobong Edoabasi Obong
COChinaecherem Peace Okafor
Chinaecherem Peace Okafor
Background: Although HIV protease inhibitors (PIs) are essential for antiretroviral therapy's viral suppression, they have also been closely linked to the emergence of dyslipidaemia and oxidative stress, two conditions that put patients at risk for cardiovascular problems. Curcumin is an active polyphenol in Curcuma longa, which has received increasing attention for its antioxidant, anti-inflammatory, and lipid-modulating properties, suggesting a potential role in mitigating drug-induced metabolic derangements. Aim: This study aimed to evaluate the ameliorative effects of curcumin on HIV PI–induced dyslipidaemia and oxidative stress in Wistar albino rats. Methods: Twenty-four adult male rats were randomized into four groups (n = 6): Control, Curcumin only (100 mg/kg), PI only (lopinavir 50 mg/kg + ritonavir 12.5 mg/kg), and PI + Curcumin (same PI regimen with curcumin supplementation introduced after two weeks of PI). Treatments were administered daily via oral gavage for six weeks. Serum lipid profile was analysed for total cholesterol, triglycerides, HDL-C, LDL-C, and TC/HDL ratio, while liver homogenates were assessed for oxidative stress markers including malondialdehyde (MDA), superoxide dismutase (SOD), catalase, and reduced glutathione (GSH). Results: Findings showed that PI treatment significantly (p<0.001) elevated lipid parameters, TC, TG, LDL-C, and TC/HDL ratio, and reduced HDL-C, while also increasing MDA and reducing antioxidant enzymes (all p<0.05). Curcumin co-treatment reversed these alterations, lowering TC and TG by ~15–20% and restoring antioxidant enzyme levels toward control values. Curcumin alone did not alter lipid or oxidative parameters. Conclusion: These findings demonstrate that curcumin may effectively mitigate PI-induced dyslipidaemia and oxidative stress, highlighting its potential as a safe adjunct to improve metabolic outcomes in HIV therapy. Further clinical research is warranted to validate these protective effects and to inform the integration of curcumin supplementation into comprehensive HIV care.

6 January 2026 in Journal of Cancer and Tumor International
Verified
Journal Article
Closed access
ROReginald Oyortey
Reginald Oyortey
TATosin Abiodun Aderanti
Tosin Abiodun Aderanti
FNFaith Chinaza Ngwoke
Faith Chinaza Ngwoke
EOEsosa Omoregie
Esosa Omoregie
AAAnointing Akindele
Anointing Akindele
UAUchechukwu Bethel Abioke
Uchechukwu Bethel Abioke
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, driven largely by KRAS mutations and profound therapeutic resistance. This review summarizes recent translational strategies aimed at bridging laboratory discoveries with clinical application, including precision oncology, rational combination therapies, and stromal modulation. We examine preclinical and clinical studies that highlight mechanistic insights such as KRAS inhibition, PARP-targeted therapy, and multi-drug regimens, drawing lessons from genetically engineered mouse models, patient-derived xenografts, and biomarker-guided clinical trials. Recent advances demonstrate that previously undruggable targets, including KRAS, can now be modulated using mutation-specific inhibitors and combination therapies, achieving complete tumor regression in preclinical models. PARP inhibitors in BRCA-mutated PDAC exemplify the translation of precision medicine into patient benefit. Adaptive, biomarker-driven trials enhance the detection of therapeutic signals, while stromal reprogramming improves drug delivery and immune accessibility. Artificial intelligence and systems biology further support predictive modeling and optimization of trial design. Overall, translational research in PDAC shows that persistent mechanistic exploration, combination strategies, and innovative trial designs can overcome historical therapeutic barriers. Despite systemic challenges such as funding, regulatory hurdles, and structural limitations, these approaches provide a roadmap for improving clinical outcomes. Continued interdisciplinary collaboration and precision-guided interventions will be essential to fully realize the potential of these discoveries.

15 April 2025 in Journal of Case Reports in Medical Science
Verified
Journal Article
Closed access
UAUchechukwu Bethel Abioke
Uchechukwu Bethel Abioke
EOEnobong Edoabasi Obong
Enobong Edoabasi Obong
TATosin Abiodun Aderanti
Tosin Abiodun Aderanti
OJOlabode Olubunmi Joy
Olabode Olubunmi Joy
ROReginald Oyortey
Reginald Oyortey
Background: Herpes simplex encephalitis (HSE) is the most common cause of sporadic viral encephalitis. It typically presents with fever, seizures, and altered mental status. If untreated, mortality can reach 70%, and among survivors, 20–60% experience long-term cognitive or functional impairment. Case Study: A 49-year-old female with well-controlled hypertension presented with sudden quadriparesis and aphasia, initially raising concern for a cerebrovascular event. However, her course evolved atypically for stroke, with progressive confusion, seizures, and cognitive decline. MRI showed temporal lobe hyperintensities, and CSF PCR confirmed HSV-1 infection, establishing herpes simplex virus encephalitis. Following acute medical management, she received an eight-week structured physiotherapy and cognitive rehabilitation program. Interventions included gait and balance training, strengthening, and functional retraining. Outcome measures such as Mini-Mental State Examination (MMSE), Berg Balance Scale (BBS), Dynamic Gait Index (DGI), and Barthel Index (BI) demonstrated marked improvements in mobility, independence, and cognition. Conclusion: This case highlights the diagnostic challenge of HSE, which can mimic stroke and Parkinsonism, while also demonstrating the potential of structured physiotherapy to achieve meaningful functional and cognitive recovery. The co-occurrence of acute cognitive changes, motor deficits, and behavioral disturbances with temporal lobe MRI abnormalities should alert clinicians to this potentially treatable disease, particularly in regions with limited diagnostic resources.

8 October 2025 in Oncology, Nuclear Medicine and Transplantology
Verified
Journal Article
Open access
PDF file
TOTosin Ayodeji Oladosu
Tosin Ayodeji Oladosu
COChinaecherem Peace Okafor
Chinaecherem Peace Okafor
PNPatrick Chinazam Nwosu
Patrick Chinazam Nwosu
AIAyo Ebunolorun Ibukunoluwa
Ayo Ebunolorun Ibukunoluwa
UMUduh Ifeoma Monica
Uduh Ifeoma Monica
TATosin Abiodun Aderanti
Tosin Abiodun Aderanti
Liquid biopsies have developed as a revolutionary technique in cancer diagnosis, treatment evaluation, and the detection of therapeutic resistance. Unlike traditional tissue biopsies, which are invasive and limited to a single temporal analysis, liquid biopsies offer a non-invasive, real-time evaluation of tumour dynamics through the analysis of biomarkers such as circulating tumour DNA (ctDNA), circulating tumour cells (CTCs), exosomes, and microRNAs. This approach enables continuous monitoring of tumour advancement, allowing for the early detection of cancer, the tracking of minimal residual disease, and the identification of emerging resistance mutations. As cancers advance and acquire resistance to therapies, liquid biopsy provides critical information that enables clinicians to customise treatment strategies and improve outcomes. Despite challenges such as sensitivity limitations in early-stage cancers and the necessity for standardised testing protocols, technological advancements, including next-generation sequencing (NGS), CRISPR, and AI-driven analytics, are enhancing the precision and accessibility of liquid biopsies. Through ongoing validation and cost-reduction efforts, liquid biopsies are set to become essential to precision oncology, offering a transformative approach to cancer therapy that could improve patient outcomes and foster equitable healthcare globally.